Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib plus bevacizumab first-line treatment for EGFR-mutant non-oligometastatic advanced NSCLC
ChiCTR2300075120Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoints: Objective response rate and Progression-free survival. Started Dec 2022; status: recruiting.
02
Drugs
almonertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300075120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075120.